Clinical Development Strategy Consultant
In brief
What does clinical development strategy consulting provide?
It translates scientific rationale, existing data and evidence gaps into a credible clinical programme designed to support the next regulatory, financing, partnering or portfolio decision.
- Best suited to
- Programmes approaching a first clinical study, proof of concept, pivotal-study commitment, financing round, partnering discussion or portfolio decision.
- Typical scope
- Indication, population, endpoint, comparator and evidence choices, with regulatory, payer, feasibility, capital and investor considerations connected.
- Expected outcome
- A decision-ready development plan that shows what the next dataset must demonstrate and which risks should be resolved before further commitment.
Expert lead: Mogens Gisselbaek, MD, MSc, physician executive and founder of Gisselbaek Consulting.
Clinical development strategy that connects science, regulatory expectations, feasibility, capital requirements and enterprise value.
Gisselbaek Consulting helps companies translate data packages, clinical assumptions and scientific rationale into credible clinical development plans. The work is especially relevant when a programme needs to become decision-ready, investable, partner-ready or better aligned with regulatory and payer expectations.
When this support is most useful
This work is often relevant before a first clinical study, proof of concept, pivotal-study commitment, financing round, partnering discussion or material portfolio decision. The goal is to test the development logic before substantial time, capital and patient participation are committed.
Support areas
- Clinical development strategy and indication prioritisation.
- Study concept, endpoint, patient population and comparator logic.
- Regulatory and payer-aligned evidence planning.
- Timeline, capital requirement and feasibility scenario analysis.
- Clinical risk architecture for investors, boards and executive teams.
The questions addressed
What decision must the next dataset earn? Which indication, endpoint, patient population and comparator choices make the programme interpretable and credible? What evidence gaps could weaken regulatory, payer, clinical or investor confidence? What risks should the board or executive team see before the programme is locked?
Who this helps
- Biotech companies preparing for first clinical study or proof of concept.
- Medtech companies defining evidence generation strategy.
- Specialty pharma teams planning lifecycle or geographic expansion.
- Investors reviewing whether a clinical path is credible and value-creating.
Support is available to organisations across the Nordics, Europe and the UK, including early- and mid-stage biotech, medtech, specialty pharma, investors and boards.
Discuss clinical development strategy support.
View all five Core Services. Related service: Investor & Board Due Diligence.